Connect with us


Research indicates certain antibiotics may be safer for the kidneys than previously believed 



Two ‘powerful’ antibiotics previously suspected of causing kidney problems in ICU patients with severe bacterial infections, particularly when used together, might be less harmful to the kidneys than previously believed.

This discovery comes from a randomized trial conducted by Vanderbilt University Medical Center (VUMC) and the Pragmatic Critical Care Research Group, with funding from several sources including grants from the National Heart Lung and Blood Institute.

ThePressNG learns that as most hospitals across the world receive one or both of these antibiotics daily, it was important to emphasize the significance of comprehending their effects comparatively, as it plays a crucial role in determining the most effective treatment for patients based on their condition and infection.

The results of the study which compared cefepime and piperacillin/tazobactam, were published in JAMA and presented by Eddie Qian, MD, who is an assistant professor of Medicine in the Division of Pulmonary and Critical Care Medicine at VUMC, during ID Week 2023 in Boston.

Qian said,

The Antibiotic Choice on Renal Outcomes (ACORN) randomized clinical trial, in the last year, compared cefepime with piperacillin/tazobactam in adults who were prescribed one of these antibiotics within 12 hours of arriving at the emergency department or medical intensive care unit in a U.S. academic medical centre.

The final analysis included 2,511 patients with a median age of 58 years. The primary outcome, which assessed the highest stage of acute kidney injury or death by day 14, showed no significant difference between the cefepime and piperacillin-tazobactam groups.

Dr. Todd Rice, a co-senior author of the study, explained,

According to Rice,

The findings from this study may provide valuable insights that could contribute to current warnings regarding the risk of renal failure in critically ill patients using piperacillin/tazobactam and the potential neurotoxicity associated with cefepime, as suggested by the authors.